SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders react to CPI data coming in lower than expected, fueling speculation about potential Fed rate cuts. The community is split, with bulls celebrating new highs and bears questioning the validity of the inflation figures and bracing for a potential pullback. Broader market sentiment appears optimistic, driving discussions about continued momentum and potential year-end targets.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a Q3 earnings beat, driven by AI PC momentum and strategic cost cuts, sparking discussions about the sustainability of these gains. The community is weighing the impact of datacenter revenue decline against the company's potential in the AI space and the influence of government investments. Analysts are split, with some highlighting the turnaround while others remain cautious about valuation and future growth.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid speculation around the latest CPI data release, with many anticipating the numbers and discussing potential market reactions. Community members are debating whether the report will be a "pump or dump" catalyst, while others express skepticism about the data's accuracy and broader market conditions. Talk of a potential Trump-Xi meeting is also circulating, adding to the market's upward momentum.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as the community discusses its strategic partnership with Palantir to accelerate enterprise AI adoption, highlighting Lumen's role in building the infrastructure for AI. Community members are debating the potential impact of this deal on Lumen's debt and future growth, with some seeing it as a game-changer and others expressing skepticism. Positive insider activity and institutional accumulation are also being noted as potential bullish signals.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest recent earnings, lowered 2025 guidance due to a supplier fire, and potential benefits from tariff relief. Community discussions revolve around the impact of these factors on Ford's future performance and whether the stock is undervalued. Bullish sentiment suggests a potential breakout, while others remain cautious due to production challenges.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending on news of soft inflation data increasing speculation around potential rate cuts, which could significantly benefit the fintech company; the community is bullish on the stock's prospects leading up to earnings, discussing a potential breakout above the $30 resistance level. Some are pointing to a similar pattern with other fintechs and anticipating that SoFi will outperform expectations.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is experiencing significant volatility after its revenue guidance fell short of expectations, sparking debate about a potential CEO change. Despite a low P/E ratio and no debt, the stock faces headwinds, with analysts divided on its future and some anticipating further downgrades. Community discussions revolve around bottom-fishing opportunities, potential bounce-backs, and whether the current dip is an overreaction.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amid concerns over renewed trade tensions after Trump's tariff threats, leading to market volatility. The community is closely watching how these developments will impact inflation and the Federal Reserve's monetary policy, especially with bank earnings coming up. Some traders believe there may be parallels to the 1929 stock market top.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending due to a potential short squeeze amplified by NVIDIA's investment and participation in the GITEX Global conference in Dubai. The community is discussing the stock's high short interest and speculating about news or catalysts. Bullish sentiment also surrounds the company's AI-driven drug discovery platform and potential expansion in the Middle East.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

Inhibrx Inc

Inhibrx (INBX) is trending due to positive trial results for their drug Ozekibart in a rare bone cancer trial, chondrosarcoma, which currently lacks approved systemic treatment options. The community is highlighting the potential for a significant improvement in patient outcomes, leading to speculation about a first-mover advantage and potential valuation increase. Some traders caution against FOMO and anticipate a possible offering given the company's cash position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics Raises $500 Million in Private Placement

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that the Company has accepted offers from multiple leading biotech institutional and individual investors to...

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments

Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.

Company News for Oct 21, 2025

Companies in The News Are: SMMT, CLF, LHX, COO

Retail buzz around Summit Therapeutics picked up Sunday after the biotech reported what it called a first-of-its-kind result in a major lung cancer study, showing that its experimental antibody ivonescimab, used alongside chemotherapy, outperformed a leading immunotherapy treatment in patients with advanced squamous non-small cell lung cancer (NSCLC).In the late-stage HARMONi-6 trial from Summit’s partner Akeso, the drug combination of ivonescimab plus chemotherapy helped people with the disease live about 11 months before their cancer worsened, compared with about 7 months for those taking the current standard therapy, tislelizumab plus chemotherapy.&nbsp;The results work out to a 40% lower risk of the disease progressing or causing death, a first for this type of lung cancer.Safety Profile Remains ManageableThe PD-1/VEGF bispecific antibody, ivonescimab, also had a manageable safety profile. Serious side effects and discontinuations of treatment were at similar rates to tislelizumab. Most VEGF-related side effects (for example, mild hypertension or proteinuria) were reversible and did not cause patients to stop treatment.Maky Zanganeh, Co-CEO and President of Summit, said the results demonstrate how ivonescimab’s novel mechanism may allow for longer treatment duration and stronger clinical benefit compared with other PD-1 and VEGF therapies given separately. “No more striking is this result than in squamous NSCLC, where the benefit of anti-VEGF therapy has been largely unrealized,” she said.Expanding To Global StudiesSummit is also advancing its HARMONi-3 global Phase III trial, designed to test ivonescimab plus chemotherapy against pembrolizumab (Keytruda) plus chemotherapy in newly diagnosed NSCLC.&nbsp;The company has now split the trial into two parts to evaluate results separately for squamous and non-squamous tumors.The squamous cohort is expected to finish enrollment in the first half of 2026, with data expected later that year, while the non-squamous group should complete enrollment in the second half of 2026.What’s The Buzz On Stocktwits?On Stocktwits, retail sentiment for Summit was ‘extremely bullish’ amid ‘high’ message volume.Some users were cautious, noting concerns about the lack of overall survival data and warning it could weigh on the stock, saying the update is “necessary by [the] FDA for approval.”<stembedurl>https://stocktwits.com/Braindead83/message/632906638</stembedurl>Others struck a more upbeat tone, with one trader expressing excitement for the market open and another calling the press release “very promising.” One user said they expected early volatility, speculating that “smart shorts” could start covering quickly once trading begins.<stembedurl>https://stocktwits.com/AlbertSan/message/632902907</stembedurl><stembedurl>https://stocktwits.com/PatrickandFrankie/message/632882531</stembedurl><a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 18% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40%

The company’s late-stage trial showed patients on ivonescimab plus chemotherapy lived 11 months longer before their cancer worsened compared with those on standard treatment, while maintaining a manageable safety profile. 

Equity

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc...

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics Inc. (NASDAQ: SMMT) ('Summit,' 'we,' or the 'Company') today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class...

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

SMMT
Summit Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SMMT News

SMMTSummit Therapeutics Inc